ALVO
NASDAQ · Biotechnology
Alvotech Sa
$3.26
+0.06 (+1.88%)
Open$3.21
Previous Close$3.20
Day High$3.32
Day Low$3.17
52W High$11.85
52W Low$3.03
Volume—
Avg Volume377.4K
Market Cap998.55M
P/E Ratio35.77
EPS$0.07
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+873.0% upside
Current
$3.26
$3.26
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 622.60M | 326.62M | 133.98M |
| Net Income | 29.53M | 13.94M | 26.13M |
| Profit Margin | 4.7% | 4.5% | 19.5% |
| EBITDA | 117.68M | 58.65M | 43.53M |
| Free Cash Flow | — | — | 33.36M |
| Rev Growth | +90.6% | +90.6% | +20.0% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |